Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | PRKDC | P78527 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 3/20 | 0.54 |
| ▸ | MAOA | P21397 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969619 | 0.95 | MAPT (0.62) | SMN1; SMN2PRKDCMAPTRAB9ANPC1 | |
| SCHEMBL13159168 | 0.86 | MAPT (0.55) | SMN1; SMN2PRKDCMAPTRAB9ANPC1 | |
| SCHEMBL7846912 | 0.86 | POLB (0.54) | SMN1; SMN2PRKDCMAPTRAB9ANPC1 | |
| SCHEMBL27953763 | 0.86 | POLB (0.54) | SMN1; SMN2PRKDCMAPTRAB9ANPC1 | |
| SCHEMBL14131672 | 0.86 | PRKDC (0.52) | SMN1; SMN2PRKDCMAPTRAB9ANPC1 | |
| SCHEMBL30964173 | 0.84 | MAPT (0.71) | SMN1; SMN2MAPTRAB9ANPC1KMT2A | |
| SCHEMBL2178470 | 0.83 | F10 (0.73) | SMN1; SMN2PRKDCMAPTRAB9ANPC1 | |
| SCHEMBL30964172 | 0.83 | MAPT (0.62) | SMN1; SMN2PRKDCMAPTRAB9ANPC1 | |
| SCHEMBL8236470 | 0.83 | JAK2 (0.68) | — | |
| SCHEMBL30964184 | 0.83 | MAPT (0.68) | SMN1; SMN2MAPTRAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115902018-A | Detection method of linezolid isomer | 江苏晨牌药业集团股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-8822458-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20130316999-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-28 | — | — | US | disclosed |
| US-8530505-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| CN-101610767-B | Combination therapy of substituted oxazolidinones | BAYER SCHERING PHARMA AG | 2013-03-13 | — | — | CN | disclosed |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| CN-1900074-B | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AG | 2012-07-11 | — | — | CN | disclosed |
| US-8129378-B2 | Rivaroxaban and derivatives, synthesis; atherosclerosis; arthritis; Alzheimer's disease or cancer | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20070197529-A1 | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard | TEVA PHARMACEUTICALS USA, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007064818-A1 | ISOLATED DESFLUORO-LINEZOLID, PREPARATION THEREOF AND ITS USE AS A REFERENCE MARKER AND STANDARD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-06-07 | — | — | WO | disclosed |
| CN-1900074-A | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER HEALTHCARE AG (DE) | 2007-01-24 | — | — | CN | disclosed |
| US-7157456-B2 | Anticoagulates for treating cardiovascular disorders, such as myocardial infarct, angina pectoris, restenoses after angioplasty, bypass, stroke; treatment of atherosclerosis, arthritis, Alzheimer's disease or cancer | BAYER HEALTHCARE AG (DE) | 2007-01-02 | — | — | US | disclosed |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| CN-1262551-C | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER AG (DE) | 2006-07-05 | — | — | CN | disclosed |
| CN-1772751-A | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER AG (DE) | 2006-05-17 | — | — | CN | disclosed |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-08-14 | — | — | US | disclosed |
| CN-1434822-A | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER AG (DE) | 2003-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | P2RY12, P2RY11, P2RY1 | SMN1; SMN2 4026/4885PRKDC 1911/4885MAPT 4859/4885 |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | SMN1; SMN2 2236/4885PRKDC 1999/4885MAPT 4752/4885 |
| US-20130316999-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | SMN1; SMN2 2236/4885PRKDC 1999/4885MAPT 4752/4885 |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | SERPINC1, XDH, SDHB | SMN1; SMN2 3300/4885PRKDC 2359/4885MAPT 4709/4885 |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | F2, F11, SERPINC1 | SMN1; SMN2 2042/4885PRKDC 2404/4885MAPT 4763/4885 |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | SMN1; SMN2 2236/4885PRKDC 1999/4885MAPT 4752/4885 |
| US-20070197529-A1 | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard | MLLT3, DAO, FHIT | SMN1; SMN2 4087/4885PRKDC 1691/4885MAPT 2666/4885 |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | F2, F11, F13B | SMN1; SMN2 2236/4885PRKDC 1999/4885MAPT 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.